Regeneron Pharmaceuticals Inc. buy Lars
Summary
This prediction ended on 21.07.22 with a price of €579.80. The BUY prediction by Lars finished with a performance of 10.50%. Lars has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Regeneron Pharmaceuticals Inc. | -2.206% | -2.206% | 32.583% |
iShares Core DAX® | -0.448% | 2.344% | 15.948% |
iShares Nasdaq 100 | 0.834% | 5.019% | 30.983% |
iShares Nikkei 225® | -0.479% | 0.550% | 9.206% |
iShares S&P 500 | -0.352% | 2.631% | 26.224% |
Comments by Lars for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren